[{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Receives the EMA PRIME Designation for Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"T lymphocyte","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to AlloVir\u2019s Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"AlloVir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlloVir, Baylor ally to develop COVID-19 T-cell therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Closes $170 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"Cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon, AlloVir Gun for $100M IPOs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AlloVir \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$276.2 million","upfrontCash":"Undisclosed","newsHeadline":"Allovir Raises $276M IPO to Run Broad Cell Therapy Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR105","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces the FDA Clearance of Investigational New Drug Application for ALVR109 for the Treatment of High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Partnership with Elevatebio to Expand TC-210 Manufacturing Capacity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"TC-210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ TCR\u00b2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation (ODD) to AlloVir\u2019s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir\u2019s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Kelonia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LVV-based GeneTherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$126.6 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces $126.6 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Kite","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children\u2019s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"iPSC-derived Allogeneic Immune Therapies","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"TCR-engineered T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","amount":"$401.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio.."}]
Find Clinical Drug Pipeline Developments & Deals by ElevateBio
Details :
The collaboration aims to explore novel approaches to improving therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR™ incubator system for cell therapy research and developme...
Details :
ALVR105 (posoleucel) is a T-lymphocyte cell therapy which is under phase 3 clinical development for the treatment of adenovirus infections, BK virus infections & Epstein-Barr virus infection.
Details :
The company intends to use the net proceeds to complete enrollment and achieve data readouts in all three of its ongoing Phase 3 trials of its lead multi-virus specific candidate, Viralym-M (posoleucel), ...
Details :
The proceeds will advance the company’s technology platforms, Life Edit gene editing, iPSCs, and RNA, cell, protein, vector engineering and BaseCamp®, to accelerate the design, manufacturing, and devel...
Details :
Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging imm...
Details :
Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging imm...
Details :
Affini-T will leverage ElevateBio BaseCamp’s LentiPeak™ lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into cli...
Details :
The partnership with CIRM reflects the novelty of the iPSC platform and recognition of next-generation cell lines that address industry challenges and could potentially save time and costs for partners de...
Details :
Peer-reviewed publication in Cell Stem Cell unveils a novel differentiation process from develop mature immune cells from induced pluripotent stem cells (iPSCs), a potentially disruptive advantage in the ...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 04, 2022
Lead Product(s) :
iPSC-derived Allogeneic Immune Therapies
Details :
AlloVir intends to use the net proceeds from the offering, to complete enrollment and achieve data readouts in all three of the Company’s ongoing Phase 3 trials of its lead multi-virus specific T-cell t...
Market Place
Reset All
